191 related articles for article (PubMed ID: 19376333)
1. Correlation between sunset glow fundus and initial dosage of corticosteroid in patients with Vogt-Koyanagi-Harada disease.
Guo YL; Du Y; He JF
Am J Ophthalmol; 2009 May; 147(5):946; author reply 946-7. PubMed ID: 19376333
[No Abstract] [Full Text] [Related]
2. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore.
Chee SP; Jap A; Bacsal K
Am J Ophthalmol; 2009 Jan; 147(1):154-161.e1. PubMed ID: 18834575
[TBL] [Abstract][Full Text] [Related]
4. Choroidal thickness in convalescent vogt-koyanagi-harada disease.
Takahashi H; Takase H; Ishizuka A; Miyanaga M; Kawaguchi T; Ohno-Matsui K; Mochizuki M
Retina; 2014 Apr; 34(4):775-80. PubMed ID: 23979311
[TBL] [Abstract][Full Text] [Related]
5. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease.
Lai TY; Chan RP; Chan CK; Lam DS
Eye (Lond); 2009 Mar; 23(3):543-8. PubMed ID: 18369377
[TBL] [Abstract][Full Text] [Related]
6. Chronic Recurrent Vogt-Koyanagi-Harada Disease and Development of 'Sunset Glow Fundus' Predict Worse Retinal Sensitivity.
Abu El-Asrar AM; Al Mudhaiyan T; Al Najashi AA; Hemachandran S; Hariz R; Mousa A; Al-Muammar A
Ocul Immunol Inflamm; 2017 Aug; 25(4):475-485. PubMed ID: 27003480
[TBL] [Abstract][Full Text] [Related]
7. Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease.
Inomata H; Rao NA
Am J Ophthalmol; 2001 May; 131(5):607-14. PubMed ID: 11336935
[TBL] [Abstract][Full Text] [Related]
8. Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation.
Keino H; Goto H; Usui M
Graefes Arch Clin Exp Ophthalmol; 2002 Oct; 240(10):878-82. PubMed ID: 12397437
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.
Read RW; Yu F; Accorinti M; Bodaghi B; Chee SP; Fardeau C; Goto H; Holland GN; Kawashima H; Kojima E; Lehoang P; Lemaitre C; Okada AA; Pivetti-Pezzi P; Secchi A; See RF; Tabbara KF; Usui M; Rao NA
Am J Ophthalmol; 2006 Jul; 142(1):119-24. PubMed ID: 16815259
[TBL] [Abstract][Full Text] [Related]
10. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome.
Agarwal M; Ganesh SK; Biswas J
Ocul Immunol Inflamm; 2006 Dec; 14(6):333-9. PubMed ID: 17162603
[TBL] [Abstract][Full Text] [Related]
11. [Vogt-Koyanagi-Harada disease].
Kjeka O; Krohn J
Tidsskr Nor Laegeforen; 2005 Aug; 125(16):2195-7. PubMed ID: 16138134
[TBL] [Abstract][Full Text] [Related]
12. Vogt-Koyanagi-Harada syndrome in a case of multiple sclerosis.
Montero JA; Sanchis ME; Fernandez-Munoz M
J Neuroophthalmol; 2007 Mar; 27(1):36-40. PubMed ID: 17414871
[TBL] [Abstract][Full Text] [Related]
13. A case of insulin dependent diabetes mellitus following systemic treatment for Vogt-Koyanagi-Harada syndrome.
Maruyama Y; Hayashi H; Takahashi K; Iino K; Kora Y
Ophthalmic Surg Lasers; 2000; 31(6):487-90. PubMed ID: 11095127
[TBL] [Abstract][Full Text] [Related]
14. [Vogt-Koyanagi-Harada syndrome in children].
Laghmari M; Karim A; Ibrahimy W; Essakalli NH; Mohcine Z
J Fr Ophtalmol; 2002 Jun; 25(6):636-40. PubMed ID: 12223954
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis of Vogt-Koyanagi-Harada-syndrome (uveoencephalitis) (author's transl)].
Sundmacher R
Klin Monbl Augenheilkd; 1975 Apr; 166(4):540-6. PubMed ID: 1206928
[TBL] [Abstract][Full Text] [Related]
16. RETINAL PIGMENT EPITHELIUM UNDULATIONS IN ACUTE STAGE OF VOGT-KOYANAGI-HARADA DISEASE: Biomarker for Functional Outcomes After High-Dose Steroid Therapy.
Hashizume K; Imamura Y; Fujiwara T; Machida S; Ishida M; Kurosaka D
Retina; 2016 Feb; 36(2):415-21. PubMed ID: 26352553
[TBL] [Abstract][Full Text] [Related]
17. A clinical grading system based on ultra-wide field retinal imaging for sunset glow fundus in Vogt-Koyanagi-Harada disease.
Lee EK; Lee SY; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):359-68. PubMed ID: 25017008
[TBL] [Abstract][Full Text] [Related]
18. [The Vogt-Koyanagi-Harada syndrome in 11-year-old girl].
Swiech-Zubilewicz A; Wróblewska E; Mańkowska A
Klin Oczna; 2005; 107(7-9):511-4. PubMed ID: 16417010
[TBL] [Abstract][Full Text] [Related]
19. Retinal vessel oxygen saturation is affected in uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; AlBloushi AF; Gikandi PW; Hardarson SH; Stefánsson E
Br J Ophthalmol; 2019 Dec; 103(12):1695-1699. PubMed ID: 30798260
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.
Feng H; Chen W; Yang J; Kong H; Li H; He Y; Wang H
BMC Ophthalmol; 2024 Jun; 24(1):238. PubMed ID: 38849758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
